Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug · Investor's Business Daily

In This Article:

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.